title: Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men.
abstract: OBJECTIVE
  Mazapertine is a structurally novel antipsychotic compound with high affinity for D2, D3, 5-HT1a, and alpha 1 receptors. The objectives were to determine whether tolerance to orthostatic hypotension caused by this compound could be induced by slowly increasing the dose administered and to investigate its effect on cognitive and motor functions.
  
  
  METHODS
  Thirteen healthy male subjects received incremental oral doses of mazapertine (from 5 to 50 mg over 7 days; n = 10) or placebo (n = 3) in part I and single doses in parts II (20 or 30 mg or placebo) and III (40 mg or placebo) in a double-blind fashion. Blood pressure, heart rate, cardiac hemodynamics, cognitive functions, and occurrence of acute extrapyramidal symptoms were investigated.
  
  
  RESULTS
  Mazapertine appears to be safe and well tolerated when administered orally for 7 days to normal healthy men. No accumulation of serum prolactin occurred after multiple dosing, suggesting limited potential for inducing galactorrhea. The drug was rapidly absorbed, and kinetics appeared to be dose dependent, without accumulation. The elimination half-life was about 5 to 10 hours. No evidence of any positive or negative cognitive effects could be detected. Mild motor symptoms were observed only at high doses (not statistically significant). Mazapertine had a minimal effect on cardiac output and stroke volume. Tolerance to hypotension could be induced by slowly increasing the dose administered.
  
  
  CONCLUSIONS
  Mazapertine is well tolerated when administered orally for seven days, and tolerance to hypotension can be induced by slowly increasing the dose administered. Therefore, nothing precludes further clinical testing on patients with schizophrenia.
authors.affiliation: Clin-Pharma Research AG, Birsfelden, Switzerland.
authors.forename: C H
authors.initials: CH
authors.lastname: Kleinbloesem
authors.forename: F
authors.initials: F
authors.lastname: Jaquet-Müller
authors.forename: Y
authors.initials: Y
authors.lastname: al-Hamdan
authors.forename: C
authors.initials: C
authors.lastname: Baldauf
authors.forename: L
authors.initials: L
authors.lastname: Gisclon
authors.forename: K
authors.initials: K
authors.lastname: Wesnes
authors.forename: C R
authors.initials: CR
authors.lastname: Curtin
authors.forename: R J
authors.initials: RJ
authors.lastname: Stubbs
authors.forename: S A
authors.initials: SA
authors.lastname: Walker
authors.forename: F
authors.initials: F
authors.lastname: Brunner-Ferber
mesh_terms: D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D003071:Cognition / Q000187:drug effects*; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004361:Drug Tolerance; D006207:Half-Life; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D011597:Psychomotor Performance / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D010879:Piperazines; C086897:mazapertine succinate